Search research articles
Contact Us
Filters
Showing results (1-10 of 7) with videos related to
Page
of 1
Sort By:
Experimental Hematology
|
December 14, 2004
Control of rHuEPO biological activity: the role of carbohydrate
Steve Elliott, Joan Egrie, Jeff Browne, et al.
Kidney International
|
May 17, 2017
Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor
Serafim Kiriakidis, Simon S Hoer, Natalie Burrows, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 30, 2008
Structure-guided design of substituted aza-benzimidazoles as potent hypoxia inducible factor-1alpha prolyl hydroxylase-2 inhibitors
Mike Frohn, Vellarkad Viswanadhan, Alexander J Pickrell, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 27, 2008
Discovery of novel hydroxy-thiazoles as HIF-alpha prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation
Christopher M Tegley, Vellarkad N Viswanadhan, Kaustav Biswas, et al.
Nature Biotechnology
|
March 4, 2003
Enhancement of therapeutic protein in vivo activities through glycoengineering
Steve Elliott, Tony Lorenzini, Sheilah Asher, et al.
Cell Reports
|
January 10, 2019
Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation
Yuting Sun, Madhavi Bandi, Timothy Lofton, et al.
Journal of Medicinal Chemistry
|
October 29, 2020
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties
Michael J Soth, Kang Le, Maria Emilia Di Francesco, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 7) with videos related to
Sort By:
Page
of 1
Experimental Hematology
|
December 14, 2004
Control of rHuEPO biological activity: the role of carbohydrate
Steve Elliott, Joan Egrie, Jeff Browne, et al.
Kidney International
|
May 17, 2017
Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor
Serafim Kiriakidis, Simon S Hoer, Natalie Burrows, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 30, 2008
Structure-guided design of substituted aza-benzimidazoles as potent hypoxia inducible factor-1alpha prolyl hydroxylase-2 inhibitors
Mike Frohn, Vellarkad Viswanadhan, Alexander J Pickrell, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 27, 2008
Discovery of novel hydroxy-thiazoles as HIF-alpha prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation
Christopher M Tegley, Vellarkad N Viswanadhan, Kaustav Biswas, et al.
Nature Biotechnology
|
March 4, 2003
Enhancement of therapeutic protein in vivo activities through glycoengineering
Steve Elliott, Tony Lorenzini, Sheilah Asher, et al.
Cell Reports
|
January 10, 2019
Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation
Yuting Sun, Madhavi Bandi, Timothy Lofton, et al.
Journal of Medicinal Chemistry
|
October 29, 2020
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties
Michael J Soth, Kang Le, Maria Emilia Di Francesco, et al.
Page
of 1